Immunodeficiency 95 (IMD95) Cell Models for Research

Immunodeficiency 95 (IMD95) is a rare primary immunodeficiency disorder caused by mutations in the CD40LG gene, which encodes the CD40 ligand (CD154) expressed on activated T cells. The disease is inherited in an X-linked recessive pattern, predominantly affecting males. The global prevalence is estimated at 1 in 1,000,000 live births, with no significant geographic variation. The condition is characterized by recurrent bacterial and opportunistic infections, particularly affecting the respiratory tract, as well as an increased risk of malignancies, especially lymphomas. Without treatment, the 5-year survival rate is low, but with hematopoietic stem cell transplantation (HSCT), survival improves significantly. According to the National Cancer Institute (NCI), patients with IMD95 have a 10-20% lifetime risk of developing cancer, primarily non-Hodgkin lymphoma. The disease is a model for studying T-cell-B-cell interactions and immunoglobulin class switching.

IMD95 is an ideal model for studying the molecular mechanisms of T-cell-dependent humoral immune responses, particularly the CD40-CD40L signaling pathway. The disease provides a clear genotype-phenotype correlation, with over 100 distinct mutations in CD40LG identified. Public datasets, such as those from the Human Gene Mutation Database (HGMD) and ClinVar, offer extensive mutation data. Key open questions include the role of CD40L in immune regulation beyond antibody production, the molecular basis of variable clinical severity, and the development of targeted therapies. Gene-edited cell models, such as CD40LG knockout T-cell lines, enable functional studies of specific mutations and the evaluation of gene therapy approaches.

IMD95 is primarily an immunodeficiency, but the defective CD40L signaling contributes to cancer susceptibility through several pathways:

• • Impaired T-cell-dependent B-cell activation: CD40L on T cells binds CD40 on B cells, essential for germinal center formation, immunoglobulin class switching, and affinity maturation. Defective signaling leads to reduced production of IgG, IgA, and IgE, and impaired memory B-cell development.
• • Increased susceptibility to oncogenic viruses: Patients have impaired immune surveillance, leading to persistent infections with Epstein-Barr virus (EBV) and human papillomavirus (HPV), which are associated with lymphomas and carcinomas.
• • Dysregulated cytokine production: Altered cytokine profiles, including reduced IL-4, IL-5, and IL-10, affect immune responses and may promote tumorigenesis.
• • Defective DNA repair mechanisms: Some studies suggest that CD40L signaling influences DNA repair pathways in B cells, and its deficiency may lead to accumulation of DNA damage.

Data from ClinVar and COSMIC.

The primary signaling network affected in IMD95 is the CD40-CD40L pathway:

• • CD40L (CD154) on T cells binds CD40 on B cells, triggering downstream signaling cascades.
• • Key downstream nodes include:
• • TRAF proteins (TRAF2, TRAF3, TRAF5, TRAF6) that mediate signal transduction.
• • NF-κB pathway (canonical and non-canonical) leading to activation of transcription factors.
• • MAPK pathway (ERK, JNK, p38) involved in cell proliferation and differentiation.
• • PI3K/AKT pathway promoting survival and metabolic changes.
• • These pathways regulate immunoglobulin class switching, germinal center formation, and memory B-cell generation.
• • Defects in CD40L lead to abrogated signaling, resulting in the clinical phenotype.

Organoids: Patient-derived organoids from tonsil or lymph node tissues can recapitulate germinal center reactions and are useful for studying T-cell-B-cell interactions. They can be generated from CD40LG-mutant cells and used for drug testing.

• • CD40LG knockout mice: These mice exhibit impaired immunoglobulin class switching and germinal center formation, mimicking the human phenotype. They are used to study immune responses and test gene therapy.
• • X-linked immunodeficiency (Xid) mice: These mice have a mutation in Bruton's tyrosine kinase (BTK) and are used as a model for X-linked agammaglobulinemia, but they also show defects in B-cell development.
• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient-derived immune cells can be used to study the disease and test therapies.
• • Induced models: CRISPR-engineered mice with specific CD40LG mutations are used to study genotype-phenotype correlations.

Gene-edited cell models are essential for studying IMD95. CRISPR-Cas9 technology allows the creation of isogenic cell lines with specific CD40LG mutations, providing a controlled system to investigate the functional consequences of each mutation. For example:

• • CD40LG knockout Jurkat cells: These cells lack CD40L expression, allowing researchers to study the effects of CD40L deficiency on T-cell activation and cytokine production.
• • CD40LG knock-in cell lines: Point mutations identified in patients can be introduced into wild-type cells to assess their impact on protein expression and function.
• • Reporter cell lines: CD40LG promoter-reporter constructs can be used to study transcriptional regulation.

These models are commercially available from various sources and are sequence-verified, ensuring reproducibility. They are invaluable for drug screening, functional genomics, and the development of gene therapy strategies.

Gene-edited cells are used to validate the function of CD40LG and other genes in the pathway. For example:

• • Knockout of CD40LG in T-cell lines confirms its role in stimulating B-cell antibody production.
• • Knock-in of patient-specific mutations allows assessment of pathogenicity and correlation with clinical severity.
• • CRISPR screens can identify modifiers of CD40L signaling, revealing new therapeutic targets.

Isogenic pairs (wild-type vs. CD40LG knockout) are used to screen for drugs that can bypass CD40L deficiency. For instance:

• • Small molecules that activate CD40 downstream signaling can be tested for their ability to restore B-cell function.
• • Gene-edited cells are used to study resistance to immunomodulatory drugs, such as those targeting CD40.
• • High-throughput screening with CRISPR-edited cells can identify compounds that enhance T-cell helper function.

CRISPR-based synthetic lethality screens in CD40LG-deficient cells can identify genes that are essential for survival in the absence of CD40L. These genes may serve as biomarkers for disease progression or as targets for therapy. Additionally, gene-edited cells can be used to identify secreted proteins that are altered in IMD95, providing potential biomarkers for diagnosis.